• Something wrong with this record ?

RX-207, a Small Molecule Inhibitor of Protein Interaction with Glycosaminoglycans (SMIGs), Reduces Experimentally Induced Inflammation and Increases Survival Rate in Cecal Ligation and Puncture (CLP)-Induced Sepsis

S. Juhas, N. Harris, G. Il'kova, P. Rehák, F. Zsila, F. Yurgenzon Kogan, O. Lahmy, R. Zhuk, P. Gregor, J. Koppel,

. 2018 ; 41 (1) : 307-314.

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18033586

The fused quinazolinone derivative, RX-207, is chemically and functionally related to small molecule inhibitors of protein binding to glycosaminoglycans (SMIGs). Composed of a planar aromatic amine scaffold, it inhibits protein binding to glycosaminoglycans (GAGs). RX-207 reduced neutrophil migration in thioglycollate-induced peritonitis (37%), inhibited carrageenan-induced paw edema (32%) and cerulein-induced pancreatitis (28%), and increased animal survival in the mouse model of cecal ligation and puncture (CLP)-induced sepsis (60%). The mechanism of RX-207 action, analyzed by UV spectroscopy, confirmed that which was elucidated for chemically related anti-inflammatory SMIGs. RX-207 binding to cell surface GAGs can account for the inhibition of neutrophil recruitment via the micro-vasculature and as a consequence, the reduction of neutrophil mediated tissue damage in the animal models of inflammation and improved survival of mice in CLP-induced sepsis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033586
003      
CZ-PrNML
005      
20181026112901.0
007      
ta
008      
181008s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10753-017-0688-0 $2 doi
035    __
$a (PubMed)29110154
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Juhas, Stefan $u Institute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia. GYN-FIV a.s., Záhradnícka 42, 821 085, Bratislava, Slovakia.
245    10
$a RX-207, a Small Molecule Inhibitor of Protein Interaction with Glycosaminoglycans (SMIGs), Reduces Experimentally Induced Inflammation and Increases Survival Rate in Cecal Ligation and Puncture (CLP)-Induced Sepsis / $c S. Juhas, N. Harris, G. Il'kova, P. Rehák, F. Zsila, F. Yurgenzon Kogan, O. Lahmy, R. Zhuk, P. Gregor, J. Koppel,
520    9_
$a The fused quinazolinone derivative, RX-207, is chemically and functionally related to small molecule inhibitors of protein binding to glycosaminoglycans (SMIGs). Composed of a planar aromatic amine scaffold, it inhibits protein binding to glycosaminoglycans (GAGs). RX-207 reduced neutrophil migration in thioglycollate-induced peritonitis (37%), inhibited carrageenan-induced paw edema (32%) and cerulein-induced pancreatitis (28%), and increased animal survival in the mouse model of cecal ligation and puncture (CLP)-induced sepsis (60%). The mechanism of RX-207 action, analyzed by UV spectroscopy, confirmed that which was elucidated for chemically related anti-inflammatory SMIGs. RX-207 binding to cell surface GAGs can account for the inhibition of neutrophil recruitment via the micro-vasculature and as a consequence, the reduction of neutrophil mediated tissue damage in the animal models of inflammation and improved survival of mice in CLP-induced sepsis.
650    _2
$a zvířata $7 D000818
650    _2
$a antiflogistika $x farmakologie $7 D000893
650    _2
$a cékum $x mikrobiologie $x chirurgie $7 D002432
650    _2
$a buněčná adheze $x účinky léků $7 D002448
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a edém $x chemicky indukované $x metabolismus $x patologie $x prevence a kontrola $7 D004487
650    _2
$a glykosaminoglykany $x metabolismus $7 D006025
650    _2
$a ligace $7 D008026
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a infiltrace neutrofily $x účinky léků $7 D020556
650    _2
$a neutrofily $x účinky léků $x metabolismus $x mikrobiologie $7 D009504
650    _2
$a pankreatitida $x chemicky indukované $x metabolismus $x patologie $x prevence a kontrola $7 D010195
650    _2
$a peritonitida $x chemicky indukované $x metabolismus $x patologie $x prevence a kontrola $7 D010538
650    _2
$a vazba proteinů $7 D011485
650    _2
$a punkce $7 D011677
650    _2
$a chinazolinony $x farmakologie $7 D052999
650    _2
$a sepse $x metabolismus $x mikrobiologie $x patologie $x prevence a kontrola $7 D018805
655    _2
$a časopisecké články $7 D016428
700    1_
$a Harris, Nicholas $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel. nharris@braude.ac.il. Ephraim Katzir Department of Biotechnology Engineering, ORT Braude Academic College of Engineering, Snonit 51, 2161002, Karmiel, Israel. nharris@braude.ac.il.
700    1_
$a Il'kova, Gabriela $u Institute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia. Institute of Animal Physiology and Genetics of the ASCR, v. v. i., Rumburská 89, 277 21, Libechov, Czech Republic.
700    1_
$a Rehák, Pavol $u Institute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia.
700    1_
$a Zsila, Ferenc $u Biomolecular Self-Assembly Group, Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
700    1_
$a Yurgenzon Kogan, Faina $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
700    1_
$a Lahmy, Orly $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
700    1_
$a Zhuk, Regina $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel.
700    1_
$a Gregor, Paul $u Rimonyx Pharmaceuticals Ltd., Rabin Science Park, 70400, Ness-Ziona, Israel. paul@gismotherapeutics.com. GISMO Therapeutics Inc., A253 ASTECC-UK, Lexington, KY, 40506, USA. paul@gismotherapeutics.com.
700    1_
$a Koppel, Juraj $u Institute of Animal Physiology, Slovak Academy of Sciences, 04001, Kosice, Slovakia.
773    0_
$w MED00002241 $t Inflammation $x 1573-2576 $g Roč. 41, č. 1 (2018), s. 307-314
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29110154 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181026113412 $b ABA008
999    __
$a ok $b bmc $g 1339514 $s 1030580
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 41 $c 1 $d 307-314 $i 1573-2576 $m Inflammation $n Inflammation $x MED00002241
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Archiving options